What is the best clinical pathological score to identify high-risk patients with lobular carcinoma of the breast who are likely to benefit from adjuvant chemotherapy?

Roberta Maltoni; Sara Bravaccini

doi:10.1007/s10549-019-05275-z

What is the best clinical pathological score to identify high-risk patients with lobular carcinoma of the breast who are likely to benefit from adjuvant chemotherapy?

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

Research output: Contribution to journal › Letter

Original language	English
Pages (from-to)	231-232
Number of pages	2
Journal	Breast Cancer Research and Treatment
Volume	177
Issue number	1
DOIs	https://doi.org/10.1007/s10549-019-05275-z
Publication status	Published - Aug 30 2019

ASJC Scopus subject areas

Oncology
Cancer Research

Cite this

Maltoni, R., & Bravaccini, S. (2019). What is the best clinical pathological score to identify high-risk patients with lobular carcinoma of the breast who are likely to benefit from adjuvant chemotherapy? Breast Cancer Research and Treatment, 177(1), 231-232. https://doi.org/10.1007/s10549-019-05275-z

@article{beba6aa13491469dabcdda83fbf1f3ef,

title = "What is the best clinical pathological score to identify high-risk patients with lobular carcinoma of the breast who are likely to benefit from adjuvant chemotherapy?",

author = "Roberta Maltoni and Sara Bravaccini",

year = "2019",

month = aug

day = "30",

doi = "10.1007/s10549-019-05275-z",

language = "English",

volume = "177",

pages = "231--232",

journal = "Breast Cancer Research and Treatment",

issn = "0167-6806",